

Bulletin #1126

February 09, 2024

NB Drug Plans Formulary Update

This update to the New Brunswick Drug Plans Formulary is effective February 9, 2024.

Included in this bulletin:

- Changes to Existing Special Authorization Benefits
- Special Authorization Approvals for Ozempic Resume

If you have any questions, please contact our office at 1-800-332-3691.

Changes to Existing Special Authorization Benefits

Generic name (Brand name)	Strength	DIN	MFR	Plans	Cost Base
------------------------------	----------	-----	-----	-------	-----------

New Strength

Semaglutide (Ozempic)	2 mg / 3 mL prefilled pen	02540258	NNO	(SA)	MLP
--------------------------	---------------------------	----------	-----	------	-----

For the treatment of type 2 diabetes mellitus when added to:

- metformin for patients who have inadequate glycemic control on metformin; or
- metformin and a sulfonylurea for patients who have inadequate glycemic control on metformin and a sulfonylurea.

Clinical Note:

- For patients who cannot take metformin due to contraindications or intolerances, details must be provided.

Claim Note:

- Approvals will be for a maximum of 1 prefilled pen every 4 weeks.

Ozempic Special Authorization Approvals Resume

The New Brunswick Drug Plans will resume considering new special authorization requests for Ozempic as Novo Nordisk Canada Inc. has advised that supply has stabilized.

Special authorization requests that were declined for patients who started Ozempic during the shortage may be resubmitted for consideration.

Due to exceptional circumstances, eligible claims with an active Special Authorization dispensed prior to February 9, 2024 may be considered for reimbursement. Pharmacies may backdate and resubmit eligible claims or members may submit a manual claim to the New Brunswick Drug Plans.